Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
every administration, there’s been a health care factor,” David Elkins, the chief financial official of Bristol Myers Squibb, ...
Fintel on MSN4d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the ...
T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
Fintel on MSN3d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb Company - Preferred Security (BMYMP) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback